NU-Body
August 10th, 2010, 11:25 AM
Latest study just in......
Erchonia Medical, the global leader in low level laser healthcare applications, announces today that its newest laser for body sculpting, Zerona, has been clinically shown to reduce the levels of the hunger-hormone, leptin, and lipoprotein (LDL). A 22 participant pilot study revealed that Zerona not only reduced circumferential inches following a two week treatment phase, but also lowered all patients’ leptin levels and reduced low-density lipoprotein numbers in over 50% of the participants in just two weeks.
Although Zerona is already positioned ahead of its competitors in terms of its ability to non-invasively, safely and effectively reduce an average of 3.64 inches around the waist, hips and thighs, this new data could have beneficial results for many patients struggling with overeating. Suppressing the very hormones that may cause individuals to be overweight or obese can further aid Zerona patients with their weight-loss goals.
Erchonia President, Steve Shanks, comments, “For most devices, the patient comes in, receives the treatment and leaves; the reason why that person was overweight or obese to begin with is not addressed. By suppressing the hunger-hormone leptin, patients’ appetites can be lessened helping them modify their diets and establish portion control going forward.”
In addition to reducing inches, suppressing hunger and reducing LDL levels, Zerona is also unique because it does not destroy fat tissue, unlike the majority of other devices on the market. Zerona promote a biological cascade within the cell provoking the formation of tiny pore or opening within the protective barrier of the cell. Then, stored fatty material leaves the cell, causing it to collapse safely.
Erchonia Medical, the global leader in low level laser healthcare applications, announces today that its newest laser for body sculpting, Zerona, has been clinically shown to reduce the levels of the hunger-hormone, leptin, and lipoprotein (LDL). A 22 participant pilot study revealed that Zerona not only reduced circumferential inches following a two week treatment phase, but also lowered all patients’ leptin levels and reduced low-density lipoprotein numbers in over 50% of the participants in just two weeks.
Although Zerona is already positioned ahead of its competitors in terms of its ability to non-invasively, safely and effectively reduce an average of 3.64 inches around the waist, hips and thighs, this new data could have beneficial results for many patients struggling with overeating. Suppressing the very hormones that may cause individuals to be overweight or obese can further aid Zerona patients with their weight-loss goals.
Erchonia President, Steve Shanks, comments, “For most devices, the patient comes in, receives the treatment and leaves; the reason why that person was overweight or obese to begin with is not addressed. By suppressing the hunger-hormone leptin, patients’ appetites can be lessened helping them modify their diets and establish portion control going forward.”
In addition to reducing inches, suppressing hunger and reducing LDL levels, Zerona is also unique because it does not destroy fat tissue, unlike the majority of other devices on the market. Zerona promote a biological cascade within the cell provoking the formation of tiny pore or opening within the protective barrier of the cell. Then, stored fatty material leaves the cell, causing it to collapse safely.